Welcome to PsychU!

Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia

Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.

Objectives:

  • Review the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)
  • List the currently available treatment recommendations and guidelines for AAD treatment recommendations
  • Identify gaps with current treatment options, both pharmacologic and nonpharmacologic

Featuring

W. Clay-Jackson

W. Clay Jackson, MD, DipTh

Assistant Professor of Clinical Psychiatry & Family Medicine University of TN College of Medicine

Bryan-Archuleta

Bryan Archuleta, PharmD (OPDC)

Senior Long-Term Care Clinical & Scientific Liaison

Speaker W. Clay Jackson, MD, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Bryan Archuleta, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources